Interindividual variability in inhibition and induction of cytochrome P450 enzymes

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 535-567

  Lin, J H ^a   Lu, A Y H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Drug interactions; Genetic polymorphism; Intestinal first pass metabolism; Quantitative prediction of drug interactions

Indexed keywords

CYTOCHROME P450;

DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FIRST PASS EFFECT; GENETIC POLYMORPHISM; PRIORITY JOURNAL; REVIEW;

ALGORITHMS; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS;

EID: 0035032568     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.535     Document Type: Review

References (136)

1. Inhibition and induction of cytochrome P450 and the clinical implications
2. Death attributed to the toxic interaction of triazolam, amitriptyline and other psychotropic drugs
3. A fatal drug interaction between clozapine and fluoxetine
4. Incidence of adverse drug interaction in hospitalized patients: A meta-analysis of prospective studies
5. Posicor: Veni, vidi and gone
6. Relevance of induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications
7. Induction of human drug-metabolizing enzymes: Mechanisms and implications
8. Sense and nonsense in the prediction of drug-drug interactions
9. Interaction of citrus juices with felodopine and nifedipine
10. Acute effect of drinking grapefruit juice on the pharmacokinetics and dynamics of felodopine and its potential clinical relevance
11. Erythromycin felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice
12. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
13. Cytochrome P450 and the individuality of species
14. Phenobarbital induction of NADPH cytochrome c(P450) oxidoreductase messenger ribonucleic acid
15. Mechanism for incorporation of proteins in membranes and organelles
16. Intralobular distribution and quantitation of cytochrome P450 enzymes in human liver as a function of age
17. Distribution of cytochromes P450, cytochrome b5, and NADPH-cytochrome P450 reductase in an entire human liver
18. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues
19. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
20. Extrahepatic metabolism of drugs in humans
21. Cytochrome P450 isozymes, epoxide hydrolase and glutathione transferase in rat and human hepatic and extrahepatic tissues
22. First-pass metabolism by gastrointestinal mucosa
23. Tissue distribution of drug-metabolizing enzymes in human
24. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
25. The immunochemical localization and distribution of cytochrome P450 in normal hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P450
26. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
27. First-pass metabolism of midazolam by the human intestine
28. (+) Bufuraloll′-hydroxylation activity in human nad rhesus monkey intestine and liver
29. Differentiation absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine
30. The nifedipine-rifampin interaction: Evidence for induction of gut wall metabolism
31. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
32. Is the role of the small intestine in first-pass metabolism overemphasized?
33. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochromeP450 3A substrate with differently modulated enzyme activity in rats
34. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P4503A and p-glycoprotein induction
35. Use of midazolam as a human cytochrome P4503 A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation
36. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test
37. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability
38. Use of midazolam as a human cytochrome P4503A probe: I. In vitro-in vivo correlations in liver transplant patients
39. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method
40. Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: Involvement of enzyme inactivation
41. Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys
42. In vivo inhibition of oxidative drug metabolism by, and acute toxicity of 1-aminobenzotriazole (ABT): A tool for biochemical toxicology
43. Enzyme induction in the cytochrome P450 system
44. Regulation of cytochrome P450 (CYP) genes by nuclear receptors
45. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
46. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene
47. Impaired (s)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9
48. Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen
49. Clearance approaches in pharmacology
50. Terfenadine-ketoconazole interaction - Pharmacokinetic and electrocardiographic consequences
51. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics: Influence of genetic polymorphism
52. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
53. The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
54. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
55. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences
56. Grapefruit juice felodipine interaction: Effect of naringin and 6′,7′-dihydroxybergamottin in humans
57. Effect of grapefruit juice on blood cyclosporin concentration
58. Interaction between grapefruit juice and midazolam in humans
59. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
60. Superiority of stable isotope techniques in the assessment of bioavailability of drugs undergoing extensive first-pass elimination: Studies of the relative bioavailability of verapamil tablets
61. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using isotope-labeling verapamil
62. Accumulation of caffeine in healthy volunteers treated with furafylline
63. i values and impact of CYP3A5 expression
64. Effect of antipsychotic drugs on human liver cytochrome P450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6
65. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes
66. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese
67. Genetic analysis of CYP2C9 polymorphism in a Japanese population
68. Allelic and functional variability of cytochrome P450 2C9
69. 359 allelic variant in the tolbutamide polymorphism
70. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
71. Differentiation of intestinal and hepatic cytochrome P450 3A activity with the use of midazolam as an in vivo probe: Effect of ketoconazole
72. The role of cytochrome P450 3A4 in alfentanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions
73. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies
74. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeperazole
75. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin
76. Inhibition and induction of human cytochrome P450 (CYP) enzymes
77. The increase in urinary excretion of 6(-hydroxycortisol) as a maker of human hepatic cytochrome P450IIIA induction
78. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
79. Induction of cytochrome P450IA genes (CYP1A) by omeprazole in human alimentary tract
80. Specific and dose-dependent enzyme induction by omeprazole in human beings
81. Gut wall metabolism of verapamil in older people: Effects of rifampicin-mediated enzyme induction
82. Rifampin drastically reduces plasma concentrations and effects of oral midazolam
83. Triazolain is ineffective in patients taking rifampin
84. Bioavailability of cyclosporin with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
85. Theophylline-rifampicin interaction: Non-selective induction of theophylline metabolic pathways
86. Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism
87. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans
88. Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath test
89. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man
90. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef
91. Effects of charcoal-broiled beef on antipyrine and theophylline metabolism
92. Dietary effect on mixed function P4501A2 activity assayed by estimation of caffeine metabolism in human
93. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: Evaluation of caffeine, oestrone and chlorzoxazone metabolism
94. Stimulatory effect of brussel sprouts and cabbage on human drug metabolism
95. Drug interactions with tobacco smoking
96. The effect of smoking on 7-ethoxyresorfin O-deethylase and other monooxygenase activities in human liver: Analysis with monoclonal antibodies
97. A form of cytochrome P450 in man, orthologus to form d in the rat, catalyzes the O-deethylation of phenacetin and is inducible by cigarette smoking
98. Induction of cytochrome P4501A by smoking or omeprazole in comparsion with UDP-glucurosyl transferase in biopsies of human duodenal mucosa
99. Effect of smoking on theophylline disposition
100. Enhanced biotransformation of theophylline in marihuana and tobacco smokers
101. Cytochrome P450 1A2 activity in man measured by caffeine metabolism: Effects of smoking, broccoli and exercise
102. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans
103. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
104. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking
105. Lack of influence of cigarette smoking on triazolam pharmacokinetics
106. Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured hepatocytes
107. The use of human hepatocyte cultures to study the induction of cytochrome P-450
108. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines
109. Effect of phenobarbital on electron transport system, oxidation and reduction of drugs in liver microsomes of rats of different age
110. Age-related alteration in the activities of drug-metabolizing enzymes and contents of sex-specific forms of cytochrome P-450 in liver microsomes from male and female rats
111. Aging, sex and the liver microsomal drug-metabolizing system in rodents and primates
112. Effects of age and gender on in vitro properties of human liver microsomal monooxygenase
113. Hepatic cytochrome P4503A (CYP3A) activity in the elderly
114. Effects of age and gender on the activity of human hepatic CYP3A
115. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions
116. Pharmacokinetic study of omeprazole in elderly healthy volunteers
117. Impaired enzyme induction by rifampicin in the elderly
118. Reduced induction of drug metabolism in the elderly
119. Ageing and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy man
120. Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin
121. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6
122. Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the C-[N-3methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin
123. Cytochrome P-450 hPCN3, a novel cytochrome P-450III gene product that is differentially expressed in adult human liver
124. Identification of a polymorphically expressed member of human cytochrome P-450III family
125. Studies on the expression and metabolic capabilities of human cytochrome P450IIIA5 (HLp3)
126. Interaction of sodium warfarin and rifampicin
127. The effects of phenobarbital, chloral betaine and glutethimide administration on warfarin plasma levels and hypoprothrombinemic responses in man
128. The effect of enzyme induction on verapamil pharmacokinetics: Verapamil-rifampicin interaction
129. Dose-dependent enzyme induction
130. Effect of pentobarbital on the disposition of alprenolol
131. Effects of chronic phenobarbital disposition in humans
132. Quinidine-rifampicin interaction
133. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
134. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: Pharmacokinetic considerations
135. In vitro approaches to predicting drug interactions in vivo